Vaxcyte, Inc. (PCVX) stock
Close on Nov 11, 2026Market cap $10.21BP/E –Yield 0.00%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $10.21B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.10
- Dividend yield
- 0.00%
- Free cash flow yield
- -9.54%
Fundamentals
- Net income
- -$1.15B
- EPS, diluted
- -$8.07
- Free cash flow
- -$974.42M
- Book value per share
- $16.72
- Diluted shares
- 149M
Trading
- Next earnings
- Feb 23, 2027 (estimated, after the close)
- Previous close
- $66.36
- Open
- $67.19
- Day's range
- $66.56 – $68.92
- Volume
- 1,622,411
- Average volume (20 days)
- 2,094,103
- Index membership
- Russell 2000 (since Sep 2020), Russell 3000 (since Nov 2020)
- Beta (5 years)
- 1.16
- 52-week range
- $42.40 – $90.75
- RSI (14 days)
- 59.5
- Volatility (1 year)
- 56.1%
- Relative volume
- 0.89×
- WACC
- 10.7%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PCVX | S&P 500 | Difference | PCVX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.9% | -2.4% | −1.5 pts | ||
| 3 months | +15.9% | -1.2% | +17.0 pts | ||
| Year to date | +48.7% | +12.3% | +36.4 pts | ||
| 1 year | +50.3% | +12.4% | +37.8 pts | ||
| 3 years | +42.5% | +78.8% | −36.3 pts | +12.5% | +21.4% |
| 5 years | +166.4% | +75.2% | +91.2 pts | +21.6% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vaxcyte filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Results
About Vaxcyte
Biological Products, (No Diagnostic Substances)
The company is a clinical-stage biotechnology firm focused on engineering innovative vaccines to protect against severe bacterial diseases. Utilizing its proprietary XpressCF cell-free protein synthesis platform, the enterprise creates broad-spectrum conjugate and novel protein vaccine candidates intended to overcome the manufacturing and immunological constraints of conventional cell-based techniques. Its primary pipeline centers on pneumococcal conjugate vaccines, highlighted by clinical candidates such as VAX-31 and VAX-24, alongside preclinical programs targeting Group A Streptococcus and Shigella infections. Intended recipients and end users encompass pediatric and adult populations susceptible to invasive bacterial illnesses and associated complications.
Company profile, executives and historyVaxcyte stock: common questions
What is Vaxcyte's stock price?
PCVX closed at $68.62 on Nov 11, 2026, up 3.41% on the day. Over the past 52 weeks it traded between $42.40 and $90.75.
What is Vaxcyte's market cap?
Vaxcyte was worth $10.21B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PCVX's P/E ratio?
Vaxcyte lost money over the twelve months to Sep 30, 2026 (diluted EPS -$8.07), so it has no meaningful P/E ratio.
Does Vaxcyte pay a dividend?
No. Vaxcyte has not paid a cash dividend over the last twelve months.
When does Vaxcyte report earnings next?
Vaxcyte is expected to report Q4 FY2026 results on Feb 23, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has PCVX stock performed over the past year?
Including dividends, PCVX returned +50.3% over the past year, against +12.4% for the S&P 500.
How many PCVX shares are sold short?
15M shares were sold short at the latest FINRA report, 10.40% of the float, or 6.7 days of average trading volume.
Who are Vaxcyte's competitors?
Companies most similar to Vaxcyte by business, industry and size include VXRT, NVAX, STRO, VIR, MRNA.
See a number that looks wrong?